Experimental ALS treatment slows disease progression by 50% in trial

FDA clears Ouralis' QRL-201 for pivotal trial planned to start in 2027

Written by Margarida Maia, PhD |

A doctor refers to a tablet while conferring with a patient, with both subjects' faces not pictured.

The U.S. Food and Drug Administration has cleared Quralis' investigational new drug application for QRL-201, allowing the company to move forward with a planned pivotal clinical trial. (Photo from iStock)

  • The experimental ALS treatment QRL-201 slowed functional decline by 50% in a clinical trial.
  • Quralis' therapy also reduced biomarkers of nerve damage.
  • The FDA cleared QRL-201 for a pivotal clinical trial, set to begin in the U.S. in the first half of 2027.

QRL-201, an experimental therapy from Quralis, slowed disease progression by 50% in people with amyotrophic lateral sclerosis (ALS) who received one of the tested doses of the therapy, according to final results from a Phase 1/2 clinical trial.

The findings come from the dose-range finding phase of the ANQUR trial (NCT05633459), in which the 10 mg dose of QRL-201 significantly slowed functional decline compared with a placebo after about eight months of treatment. The lower 3 mg dose also showed a slowing of functional decline, and both doses were associated with significant reductions in biomarkers of nerve damage.

Now, the U.S. Food and Drug Administration (FDA) has cleared Quralis’ investigational new drug (IND) application for QRL-201, allowing the company to move forward with a planned pivotal clinical trial, called CONQUR, in the U.S. The company expects to start the trial in the first half of 2027.

“We are delighted to receive FDA clearance of the IND for QRL-201, our lead program in ALS, marking an important milestone for QurAlis and highlighting the Agency’s support for rare diseases like ALS,” Kasper Roet, PhD, CEO and co-founder of QurAlis, said in a company press release. “We are equally encouraged by the final results from the ANQUR clinical trial evaluating QRL-201 in ALS patients, which show a remarkable slowing of the disease. QurAlis looks forward to progressing the pivotal CONQUR clinical trial of QRL-201 in ALS.”

Recommended Reading
An up-close illustration of a strand of DNA highlights its double-helix structure.

Experimental treatment shows promise in patient with rare genetic form of ALS

QRL-201 designed to help restore levels of key protein

While a protein called TDP-43 normally resides in the cell nucleus, where DNA is stored, the vast majority of people with ALS have a faulty TDP-43 protein that accumulates outside the nucleus and forms toxic clumps that can damage nerve fibers.

The loss of TDP-43 from the nucleus also leads to problems in how cells process RNA, the molecule that carries instructions from DNA to produce proteins. One of the genes that is incorrectly processed is STMN2, which reduces production of stathmin-2, a protein needed to keep nerve fibers stable and to help them regenerate after damage.

QRL-201 is an antisense oligonucleotide — a short strand of genetic material — designed to prevent the incorrect processing of STMN2. This is expected to restore levels of the stathmin-2 protein and help protect nerve fibers, potentially slowing disease progression in people with ALS.

Recommended Reading
An illustration shows a woman walking briskly, with red-rimmed circles in the background.

Experimental treatment may help preserve body weight in ALS, data show

Therapy reduced biomarkers of nerve damage

The ANQUR trial is evaluating QRL-201 in people with sporadic ALS or ALS associated with mutations in the C9orf72 gene, a common genetic cause of ALS. It is being conducted in three parts.

An initial multiple ascending phase tested two doses of QRL-201 — 10 mg and 20 mg — against a placebo in 17 patients. Its dose-range finding phase included 52 participants with sporadic ALS who were randomly assigned to receive 3 mg or 10 mg of QRL-201 or a placebo. The therapy was administered by injection into the spinal canal, allowing it to reach the brain and spinal cord.

The main goal of ANQUR is to test the safety and tolerability of QRL-201. It is also assessing the therapy’s pharmacokinetics, or how it moves into, through, and out of the body.

Results showed that QRL-201 was generally safe and well tolerated across all phases of the ANQUR study. Most side effects were mild or moderate, and no serious adverse events have been reported.

In the dose-range finding phase, participants receiving the 10 mg dose had a 50% slower functional decline, measured using the ALS Functional Rating Scale-Revised, than those receiving a placebo after 253 days (or about 8.3 months). This difference was statistically significant.

The findings from the ANQUR clinical trial are promising and justify additional clinical research into QRL-201 as a potential treatment option for individuals with sporadic ALS.

In patients receiving the 3 mg dose, phosphorylated neurofilament heavy chain, a protein released when nerve fibers are damaged, decreased significantly by 46% in spinal fluid. Another biomarker of nerve damage, neurofilament light chain (NfL), decreased in the blood by 18% in the 3 mg group and by 36% in the 10 mg group.

An earlier analysis had already shown that QRL-201 can reach and engage with its target and restore levels of stathmin-2 in the brain and spinal cord.

“The findings from the ANQUR clinical trial are promising and justify additional clinical research into QRL-201 as a potential treatment option for individuals with sporadic ALS,” said Merit E. Cudkowicz, MD, director of the Sean M. Healey & AMG Center for ALS and executive director of the Neuroscience Institute at Mass General Brigham in Boston. Cudkowicz is also a member of Quralis’ clinical advisory board.

Based on these findings, ANQUR has now moved into its open-label extension phase. Currently, 41 patients in the European Union, Canada, and the U.K. are receiving the 3 mg dose of QRL-201.

Leave a comment

Fill in the required fields to post. Your email address will not be published.

Comments are moderated. Once approved, your comment and username will be publicly visible. Please avoid sharing personal health information or other sensitive details.